APTOF — Aptose Biosciences Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 882361 ·
Ontario, Canada
Last close
$1.68
Market Cap
$4.29M
52W High
$1.74
52W Low
$1.55
ADV30
2,195
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -7,428,000 | -7,759,000 | 10,012,000 | 935,000 | 37,179,000 |
| Sep 2025 | 0 | — | -4,913,000 | -5,123,000 | 6,341,000 | 613,000 | 25,791,000 |
| Jun 2025 | 0 | — | -6,921,000 | -7,043,000 | 5,591,000 | 553,000 | 19,962,000 |
| Mar 2025 | 0 | — | -5,461,000 | -5,543,000 | 7,467,000 | 4,700,000 | 14,860,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,990,000
Investing CF
$0
Financing CF
$19,379,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-18.71
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-566,435,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-24,623,000
Pretax Income TTM
$-25,468,000
Interest Exp TTM
$84,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,723,000 | -25,468,000 | 10,012,000 | 37,179,000 | — | -21,990,000 |
| Dec 2024 | 0 | -26,257,000 | -25,430,000 | 10,127,000 | 14,670,000 | — | -35,977,000 |
| Dec 2023 | 0 | -52,356,000 | -51,207,000 | 12,989,000 | 15,890,000 | — | -44,590,000 |
| Dec 2022 | 0 | -42,602,000 | -41,823,000 | 51,027,000 | 13,286,000 | — | -32,322,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VIVS | VivoSim Labs, INC. | $3.73M | $1.29 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $5.03M | $0.69 | — |
| CLDI | Calidi Biotherapeutics, Inc. | $3.42M | $0.18 | — |
| AIM | AIM ImmunoTech Inc. | $3.39M | $0.23 | — |
| BCAB | BioAtla, Inc. | $6.48M | $3.91 | — |
News headlines (Yahoo Finance, 1h cache)
Aptose Reports First Quarter 2026 Results
2026-05-13 21:00 · Yahoo
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
2026-04-30 11:30 · Yahoo
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
2026-03-31 21:22 · Yahoo
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
2026-03-23 11:30 · Yahoo
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
2026-03-19 11:30 · Yahoo
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
2026-02-24 12:00 · Yahoo
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
2025-12-19 22:05 · Yahoo
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
2025-12-06 13:00 · Yahoo
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
2025-11-19 06:22 · Yahoo
Aptose Biosciences: Q3 Earnings Snapshot
2025-11-13 22:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.